August 3 -- Wuhan National Pharmaceutical Technology (600421.SH) filed it will cancel its restructuring plan with Shanghai Kaidi Group due to tightened real estate regulations, reports yicai.com.

As filed in 2009, National Pharmaceutical will offer 509 million shares to Yangfan Investment (Shanghai) and Xu Jin at 4.53 yuan per share to fully acquire Shanghai Kaidi, which is valued at  two to 2.5 billion yuan. Meanwhile, the company will transfer its 100-percent stake in Wuhan Yekaitai Pharmaceutical Chain, its 98-percent stake in Wuhan Spring Pharmaceutical Sales, the equipment and machinery of its factory in Ezhou city, and all its accounts receivable to its parent, Wuhan New Generation Technologies. Shanghai Kaidi will thus complete its backdoor listing through National Pharmaceutical.

Shandong Demian (RCode:002072) and Far East Industrial (RCode:000681) both cancelled their backdoor listing plans for the same reasons in June. Nevertheless, Macrolink Real Estate (RCode:000620), Gansu Languang Science and Technology (RCode:000981), and Jinke Property Group (RCode:000656) were all approval by the China Securities Regulatory Commission for their own backdoor listing restructurings.